Allogene Therapeutics CFO Geoffrey Parker to retire in November 2026
The company disclosed in an SEC filing that its finance chief will step down effective November 6, 2026.
SEC filing
Latest
2 stories
Wednesday, September 2
Wednesday, August 12
Allogene reports Q2 2026 results, cites ALPHA3 futility data and FDA designations for cema-cel
The company said an interim futility analysis in its Phase 2 ALPHA3 trial supported cema-cel's use in first-line LBCL, and the FDA granted RMAT and Fast Track status after reviewing that data.
SEC filing